ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $460,791 | -54.7% | 86,778 | -18.7% | 0.00% | – |
| Q2 2023 | $1,017,328 | +47.7% | 106,750 | +70.4% | 0.00% | – |
| Q1 2023 | $688,985 | +1253.3% | 62,635 | +1720.8% | 0.00% | – |
| Q4 2022 | $50,913 | -30.3% | 3,440 | -10.9% | 0.00% | – |
| Q3 2022 | $73,000 | -6.4% | 3,862 | +5.3% | 0.00% | – |
| Q2 2022 | $78,000 | -97.1% | 3,666 | -97.4% | 0.00% | -100.0% |
| Q1 2022 | $2,672,000 | -9.0% | 138,735 | -2.0% | 0.00% | 0.0% |
| Q4 2021 | $2,936,000 | -84.1% | 141,562 | -81.7% | 0.00% | -75.0% |
| Q3 2021 | $18,472,000 | -24.6% | 773,214 | -13.9% | 0.00% | -20.0% |
| Q2 2021 | $24,505,000 | -3.4% | 897,972 | +2.4% | 0.01% | -16.7% |
| Q1 2021 | $25,360,000 | +40.1% | 876,584 | +36.2% | 0.01% | +50.0% |
| Q4 2020 | $18,101,000 | +11.0% | 643,456 | +15.7% | 0.00% | -20.0% |
| Q3 2020 | $16,301,000 | +2.3% | 556,363 | +5.5% | 0.01% | 0.0% |
| Q2 2020 | $15,941,000 | +29.3% | 527,127 | +27.4% | 0.01% | +25.0% |
| Q1 2020 | $12,331,000 | – | 413,771 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
| Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
| 1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
| Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
| MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
| Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
| SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
| Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |